Related Experiment Video
Updated: Mar 19, 2026
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
Paul Glaucoma Implant Versus Ahmed Glaucoma Valve in Pediatric Glaucoma Following Congenital Cataract Surgery
Angi Lizbeth Mendoza-Moreira1, Julia V Stingl, Peter Wolfrum
1Department of Ophthalmology, University Medical Centre Mainz, Mainz, Rheinland-Pfalz, Germany.
Insights
The Paul Glaucoma Implant (PGI) and Ahmed Glaucoma Valve (AGV) are effective for lowering intraocular pressure in children with glaucoma after cataract surgery. Both implants demonstrated a good safety profile and comparable surgical success rates.
Area of Science:
- Ophthalmology
- Pediatric Glaucoma Management
- Surgical Implants
Background:
- Glaucoma following congenital cataract surgery (GFCS) requires effective intraocular pressure (IOP) management.
- The Paul Glaucoma Implant (PGI) and Ahmed Glaucoma Valve (AGV) are commonly used glaucoma drainage devices.
Purpose of the Study:
- To compare the effectiveness and safety of PGI versus AGV in pediatric patients with GFCS.
- Evaluate IOP reduction, medication needs, and surgical success rates for both implants.
Main Methods:
- Retrospective study of children (0-17 years) with GFCS.
- Compared outcomes of PGI implantation with a historical cohort treated with AGV.
- Primary outcomes: IOP reduction and antiglaucoma medication count; Secondary outcomes: surgical success and complications.
Main Results:
- Both PGI and AGV significantly reduced IOP after one year.
- 100% qualified/complete success with PGI vs. 85.7% with AGV.
- No serious complications were reported for either implant.
Conclusions:
- PGI and AGV offer comparable efficacy and safety for managing pediatric glaucoma post-cataract surgery.
- Both implants are viable options for lowering IOP in this patient population.
- Further research may explore long-term outcomes and specific indications.
Prcis:
Both PGI and AGV can be used to lower intraocular pressure with a good safety profile in children with glaucoma following cataract surgery.
Purpose:
To compare the effectiveness and safety of the Paul Glaucoma Implant (PGI) and the Ahmed Glaucoma Valve (AGV) in children with glaucoma following congenital cataract surgery (GFCS).
Patients And Methods:
This retrospective study included children aged 0-17 years with GFCS who underwent PGI implantation at a tertiary center between 2022 and 2024, with at least 1 year of follow-up. Outcomes were compared with a retrospective cohort treated with AGV. Primary outcomes were a reduction in intraocular pressure (IOP) and the number of antiglaucoma medications. Secondary outcomes included surgical success, defined as IOP ≤21 mm Hg and ≥6 mm Hg without failure criteria. Failure was defined as 2 consecutive IOP measurements outside the target after 3 months, need for oral acetazolamide, reoperation, implant explantation, or loss of light perception. Intraoperative and postoperative complications were recorded.
Results:
Fourteen eyes from 12 patients (7 per group) completed 1-year follow-up. Mean IOP decreased significantly in both groups, from 26.7±5.2 to 14.4±3.0 mm Hg in the AGV group and from 30.4±9.7 to 12.6±4.5 mm Hg in the PGI group, with no significant intergroup difference. Median medication use decreased from 3 (IQR: 0) to 0 (IQR: 1) in the AGV group and from 4 (IQR: 1) to 2 (IQR: 2) in the PGI group. Complete or qualified success was achieved in 85.7% of AGV eyes and 100% of PGI eyes. No serious complications occurred.
Conclusion:
PGI and AGV showed comparable efficacy, safety, and surgical success in children with GFCS.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
01:25Glaucoma: Overview
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...